Loading organizations...

§ Private Profile · San Diego, CA, USA
Biotechnology company developing immune system cancer therapeutics.
Rybodyn pioneers immunotherapy development by decoding the "dark proteome," a hidden universe of biological signals beyond traditional sequencing. Its proprietary RyboCypher™ platform integrates advanced RNA sequencing with AI models, trained on extensive transcriptomic and proteomic data. This approach identifies and validates cryptic therapeutic targets, developing novel antibody-based drug candidates for unmet medical needs.
Co-founded by Imad Ajjawi, PhD, MBA, and Corey Dambacher, PhD, Rybodyn launched in early 2025. Its genesis came from Dr. Dambacher's research, revealing the "dark genome" harbored a previously uncharacterized proteome. This pivotal insight into overlooked genetic information directly spurred Rybodyn's formation.
Rybodyn targets critical unmet medical needs, focusing primarily on cancer immunotherapy. The company's pipeline translates newly discovered Cryptic Targets™ into viable clinical drug candidates. Its vision is to redefine patient care, delivering innovative immunotherapies for complex diseases by transforming novel discoveries into effective clinical solutions.
Rybodyn has raised $14.0M across 2 funding rounds.
Rybodyn has raised $14.0M in total across 2 funding rounds.
Rybodyn has raised $14.0M across 2 funding rounds. Most recently, it raised $10.0M Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2026 | $10M Seed | Genedant, SeaX Ventures, August LEE, Supachai KID Parchariyanon | Genedant, Eric Woersching, Polygon Ventures, SeaX Ventures, SOSV, Swell Partners | Announced |
| Jan 1, 2025 | $4M Seed | SeaX Ventures, August LEE | Alumni Ventures, BoxOne Ventures, Builders VC, First Round Capital, SNR, Zaka Ventures, Varsha RAO | Announced |
Rybodyn has raised $14.0M in total across 2 funding rounds.
Rybodyn's investors include Genedant, SeaX Ventures, August Lee, Supachai Kid Parchariyanon, Eric Woersching, Polygon Ventures, SOSV, Swell Partners, Alumni Ventures, BoxOne Ventures, Builders VC, First Round Capital.
Rybodyn is an AI-driven biotech that discovers previously unrecognized proteins from the “dark” (formerly considered non‑coding) regions of the genome and converts those discoveries into antibody‑based and other immunotherapies via its proprietary RyboCypher™ platform[1][2]. RyboDyn focuses on turning *Cryptic Targets™* from the dark proteome into first‑in‑class therapeutics for cancer and other diseases, combining high‑resolution RNA sequencing, mass‑spectrometry validation and AI to reveal targets standard methods miss[1][2].
High‑Level Overview
For the portfolio / product view
Origin Story
Core Differentiators
Role in the Broader Tech & Biotech Landscape
Quick Take & Future Outlook
Quick take: Rybodyn is a focused, early‑stage biotech building a differentiated, platform‑led route from novel dark‑proteome discovery to therapeutics; its near‑term value hinges on robust preclinical validation and whether cryptic targets translate into safe, efficacious clinical candidates[1][3][4].
Sources: Rybodyn corporate site and About page[1][2]; IndieBio / SOSV profile on Rybodyn[3]; company press release on discovery and $4M pre‑seed[4]; industry article on selection to Lilly Gateway Labs[5].